{"organizations": [], "uuid": "a245bad1649cfa9099a0e60c20dba357efa4863c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-arbutus-and-roivant-launch-genevan/brief-arbutus-and-roivant-launch-genevant-sciences-with-platform-to-develop-broad-range-of-rna-therapeutics-for-genetic-diseases-idUSFWN1RO0Z0", "country": "US", "domain_rank": 408, "title": "BRIEF-Arbutus And Roivant Launch Genevant Sciences With Platform To Develop Broad Range Of RNA Therapeutics For Genetic Diseases", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-12T00:41:00.000+03:00", "replies_count": 0, "uuid": "a245bad1649cfa9099a0e60c20dba357efa4863c"}, "author": "", "url": "https://www.reuters.com/article/brief-arbutus-and-roivant-launch-genevan/brief-arbutus-and-roivant-launch-genevant-sciences-with-platform-to-develop-broad-range-of-rna-therapeutics-for-genetic-diseases-idUSFWN1RO0Z0", "ord_in_thread": 0, "title": "BRIEF-Arbutus And Roivant Launch Genevant Sciences With Platform To Develop Broad Range Of RNA Therapeutics For Genetic Diseases", "locations": [], "entities": {"persons": [{"name": "deve", "sentiment": "negative"}], "locations": [{"name": "cambridge", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "paris panayiotopoulos", "sentiment": "none"}, {"name": "massachusetts", "sentiment": "none"}, {"name": "basel", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}], "organizations": [{"name": "alnylam", "sentiment": "none"}, {"name": "rna therapeutics for genetic diseases reuters staff    arbutus biopharma corp", "sentiment": "none"}, {"name": "takeda", "sentiment": "none"}, {"name": "ligand", "sentiment": "none"}, {"name": "mrna", "sentiment": "none"}, {"name": "lnp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 11 (Reuters) - Arbutus Biopharma Corp:-\n* LEADING PLATFORM TO DEVELOP BROAD RANGE OF RNA THERAPEUTICS FOR GENETIC DISEASES\n* GENEVANT WILL BE LED BY EXECUTIVE CHAIRMAN PARIS PANAYIOTOPOULOS, FORMER CEO OF ARIAD PHARMACEUTICALS THROUGH ITS 2017 ACQUISITION BY TAKEDA\n* GENEVANT AIMS FOR 5-10 PRODUCT CANDIDATES INTO CLINIC BY 2020 ACROSS RNAI, MRNA, GENE EDITING MODALITIES USING CO’S LNP, LIGAND CONJUGATE PLATFORMS\n* GENEVANT INTENDS TO ESTABLISH ITS U.S. HQ IN CAMBRIDGE, MASSACHUSETTS & ITS PRINCIPAL OPERATING CO IN BASEL, SWITZERLAND\n* UNDER TERMS OF AGREEMENT, ROIVANT SCIENCES WILL CONTRIBUTE $37.5 MLN IN TRANSACTION-RELATED SEED CAPITAL FOR GENEVANT\n* CO WILL RETAIN ENTIRETY OF ITS ROYALTY ENTITLEMENT ON COMMERCIALIZATION OF ALNYLAM PHARMACEUTICAL’S PATISIRAN\n* WILL RETAIN ALL RIGHTS TO LNP AND CONJUGATE DELIVERY PLATFORMS FOR HEPATITIS B VIRUS Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-12T00:41:00.000+03:00", "crawled": "2018-04-12T00:54:22.006+03:00", "highlightTitle": ""}